Survival Effect of Lung Transplantation Among Patients With Cystic Fibrosis
Authors:
- Theodore G. LiouTLTheodore G. Liou
- Frederick R. AdlerFAFrederick R. Adler
- Barbara C. CahillBCBarbara C. Cahill
- Stacey C. FitzSimmonsSFStacey C. FitzSimmons
- David HuangDHDavid Huang
- Jonathan R. HibbsJHJonathan R. Hibbs
- Bruce C. MarshallBMBruce C. Marshall
Open Access
- 5 December 2001
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 286 (21) , 2683-2689
Abstract
Cystic fibrosis (CF) is an autosomal recessive, multisystem disease leading to significant morbidities and early death. Treatments for pancreatic and pulmonary manifestations have improved median survival in the United States from less than 6 months to about 32 years in 1998.1 Severe pulmonary disease is the primary cause of mortality in CF, underlying 76.4% of deaths in 1998.1Keywords
This publication has 28 references indexed in Scilit:
- Timing of Referral for Lung Transplantation for Cystic FibrosisChest, 1999
- Spirometric Reference Values from a Sample of the General U.S. PopulationAmerican Journal of Respiratory and Critical Care Medicine, 1999
- International Guidelines for the Selection of Lung Transplant CandidatesAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Lung Transplantation in Cystic FibrosisChest, 1998
- Living-donor lobar lung transplantation experience: Intermediate resultsThe Journal of Thoracic and Cardiovascular Surgery, 1996
- Improved results of lung transplantation for patients with cystic fibrosisThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Prediction of Mortality in Patients with Cystic FibrosisNew England Journal of Medicine, 1992
- Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosisThe American Journal of Medicine, 1987
- Biostatistical Analysis.Journal of the American Statistical Association, 1975
- A new prognostic score and clinical evaluation system for cystic fibrosisThe Journal of Pediatrics, 1973